Citius Pharma Posts $7.1M LYMPHIR Revenue, 383 Vial Orders in July
CTXR sits 61% above its 52-week low of $0.469.
Summary
Citius Pharmaceuticals reported fiscal Q3 2026 results with $7.1 million in LYMPHIR revenue for the first nine months and $17 million in cash as of June 30. The launch is accelerating: new institutions ordering the drug rose 80%, institutional vial orders grew 31%, and July hit a record 383 vials. The company also completed deployment of a 29-person commercial and medical affairs team through EVERSANA. Phase 1 data presented at ASCO and ASTCT/CIBMTR showed durable responses in gynecologic cancers and an 86% ORR in DLBCL prior to CAR-T, supporting expansion beyond CTCL. This follows the August 5 update showing 78% growth in new accounts and the recent board expansion at Citius Oncology. The revenue figure is modest relative to the company's market cap, but the accelerating order trend and near-universal payer coverage suggest the launch is gaining real traction. Watch for continued monthly vial order growth and any updates on the $25 million term loan facility.
At the time of this announcement, CTXR was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.7M. The 52-week trading range was $0.47 to $2.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.